AxoGen, Inc. Announces Third Quarter 2012 Financial Results

ALACHUA, Fla.--(BUSINESS WIRE)--AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions, today announced revenues for the third quarter ended September 30, 2012 of $1.98 million, a 74% increase over revenues of $1.14 million in the third quarter 2011.

Back to news